Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks.

OBJECTIVE: To investigate whether first-trimester maternal plasma fetal fraction is altered in women that subsequently develop preeclampsia (PE) or gestational hypertension (GH) and to examine its potential value in improving the performance of screening for PE and GH by maternal factors and maternal serum pregnancy associated plasma protein-A (PAPP-A), mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI). METHODS: The study population of 10,131 pregnancies undergoing cell free fetal DNA testing at 11-13 weeks' gestation included 91 (0.9%) cases with preterm-PE, 222 (2.2%) cases with term-PE, 360 (3.6%) with GH and 9,458 (93.4%) cases unaffected by hypertensive disorders. Maternal plasma fetal fraction levels were expressed as multiples of the median (MoM) after adjustment for maternal factors and crown-rump length. The performance of screening for preterm-PE, term PE and GH by maternal factors and MoM values of fetal fraction, PAPP-A, UtA-PI and MAP was evaluated by receiver operating characteristic (ROC) curves. RESULTS: The median fetal fraction MoM was significantly lower in the preterm-PE (0.825; IQR 0.689-1.115 MoM, p < .001), term-PE (0.946; IQR 0.728-1.211 MoM, p = .028) and GH (0.928; IQR 0.711-1.182 MoM, p < .001) groups than in the unaffected group (1.002; IQR 0.785-1.251 MoM). However, the performance of screening for PE or GH by maternal factors alone or by maternal factors and PAPP-A, UtA-PI and MAP was not significantly improved by the addition of fetal fraction. CONCLUSIONS: First trimester maternal plasma fetal fraction is not useful in screening for hypertensive disorders of pregnancy.

Evolución y costes de la prematuridad por indicación médica en un hospital de tercer nivel / Evolution and costs of the medically indicated preterm birth in a tertiary care university hospital

INTRODUCCIÓN Y OBJETIVO: Analizar la evolución y los costes de los partos prematuros iatrogénicos en un hospital universitario de tercer nivel. MÉTODOS: Estudio de cohortes retrospectivo de los partos con edad gestacional comprendida entre 24 y 36+6 semanas en dos periodos temporales: 2001-2005 y 2011-2016. Se identificaron los partos prematuros por indicación médica o iatrogénicos (PPI). Se analizaron variables demográficas y de resultado. Los costes se calcularon mediante el grupo relacionado con el diagnóstico (GRD) de cada ingreso. RESULTADOS: Se obtuvo una muestra de 620 partos prematuros iatrogénicos. La tasa de prematuridad global se mantuvo estable en 9%. La tasa de prematuridad iatrogénica experimentó un incremento relativo del 9,7%. Entre las pacientes con un PPI se apreció un incremento en la edad materna de 27,7 a 32,9 años, de la obesidad (32,2% a 55,5%) y del uso de técnicas de reproducción asistida (6% a 11,1%). Preeclampsia y retraso del crecimiento (CIR) fueron las principales causas de PPI, en los que se incrementó la tasa de cesáreas de 66,9% a 78%, la estancia media de 7,8 días a 9,6 y el coste por paciente de 3.068,6 a 7.331,9 euros. CONCLUSIONES: Se observa un aumento de PPI en el segundo periodo, manteniéndose la prematuridad global. Los cambios demográficos podrían explicar este incremento. Estos cambios están implicados en la fisiopatología de la preeclampsia y el CIR y en el aumento de su incidencia. La prevención primaria y secundaria de esas complicaciones podría reducir la incidencia y los costes de la prematuridad iatrogénica.

INTRODUCTION AND OBJECTIVES: To evaluate the incidence, evolution, causes and costs of premature births (PB) due to medical indication (iatrogenic) in a tertiary care university hospital METHODS: Retrospective cohort study of all deliveries with gestational age between 24 and 36+6 weeks, in two periods 2001-2005 and 2011-2016. Iatrogenic births were identified. Clinical, epidemiological, diagnostic and economic variables were analysed. RESULTS: A sample size of 620 iatrogenic deliveries was obtained. We found a 9.7% relative increase in iatrogenic prematurity rate in the second period as well as an increase in maternal age from 27.7 to 32.9, obesity from 32.2% to 55.5% and the use of assisted reproductive techniques from 6% to 11.1%. Preeclampsia and intrauterine growth restriction were found to be the main causes of iatrogenic premature delivery. In these cases the rates of cesarean section increased from 66.9% to 78%. The average stay per patient and the cost calculated by diagnosis related group (DRG) also showed a statistically significant increase from 7.8 days and 3,068.6 euros to 9.6 days and 7,331.9 euros. CONCLUSIONS: We observed an increase in iatrogenic prematurity in the second period despite the unchanged rate of spontaneous PB. Demographic changes in the population, as well as an increase in obstetric related conditions, seem to be responsible for this increase. Primary and secondary prevention of clinical characteristics may reduce the incidence and costs derived from this type of prematurity.

Falsos positivos del cribado de trisomía 21 y 18 del primer trimestre y complicaciones obstétricas / Adverse outcomes in pregnancies with false positive trisomy 21 and 18 screening results

OBJETIVO: Analizar si los casos positivos de cribado combinado de trisomía 21 (t21) o trisomía 18 (t18) en ausencia de aneuploidía (falsos positivos- FP) se relacionan con complicaciones de la gestación, ajustando por factores demográficos y clínicos de riesgo. MATERIAL Y MÉTODOS: Estudio retrospectivo de casos y controles anidado en una cohorte de pacientes que acudieron para cribado del primer trimestre. Los casos fueron las pacientes con FP de riesgo combinado de t21 superior a 1/270 o riesgo de t18 superior a 1/100. Se consideraron complicaciones de la gestación: óbito fetal, parto prematuro menor de 34 semanas o prematuro menor de 37 semanas, preeclampsia, retrasos de crecimiento, pequeño para la edad gestacional (CIR, PEG) y diabetes gestacional (DG). Se ajustó por obesidad, edad, paridad, tabaquismo, y técnicas de reproducción asistida. RESULTADO: Se obtuvieron 204 casos de FP, 149 FP para trisomía 21, 41 para trisomía 18, y 14 FP para ambos riesgos. Se encontró asociación estadísticamente significativa de FP t21 con óbito fetal (OR=3,5; ic95% 1,4-8,7; p=0,01), parto prematuro menor de 37 semanas (OR=2,2; IC95% 1,4-3,4; p=0,001), preeclampsia (OR =2,6; IC95% 1,17-6,1; p=0,02), PEG (OR =2,2; IC95% 1,2-4,1; p=0,02), CIR (OR=2,8; IC95% 1,6-5,1; p=0,001), y DG (OR=2,1; IC95% 1,2-3,7; p=0,01). Los FP t18 se asociaron con óbito (OR=8,9; IC95% 2,9-27; p=0,002). CONCLUSIÓN: Los FP del cribado del primer trimestre, para trisomía 21 y trisomía 18, se asocian con resultados obstétricos adversos.

We have studied whether positive cases of combined trisomy 21 (t21) or 18 (t18) screening in the absence of aneuploidy (false positives -FP-) are related to pregnancy complications adjusting for demographic and clinical risk factors. METHODS: Retrospective case-control study nested in a cohort of patients who came for first trimester aneuploidy screening. The cases were patients with FP combined risk of t21 (greater than 1/270) or t18 risk (greater than 1/100). The control group was a sample of patients with low-risk screening. We considered pregnancy complications: stillbirth, premature delivery before 34 and 37 weeks, preeclampsia, growth retardation, small for gestational age (FGR, SGA), and gestational diabetes (GD). Or were adjusted for obesity, age, parity, smoking, and assisted reproduction techniques. RESULTS: 204 cases of FP were obtained, 149 FP for trisomy 21, 41 for trisomy 18, and 14 FP for both risks. A statistically significant association between t21 FP was found with stillbirth (OR = 3.5; 95% CI 1.4-8.7; p = 0.01), preterm delivery less than 37 weeks (OR = 2.2; 95% CI 1.4-3.4; p = 0.001), preeclampsia (OR = 2.6; 95% CI 1.17-6.1; p = 0.02), SGA (OR = 2.2; 95% CI 1, 2-4.1; p = 0.02), FGR (OR = 2.8; 95% CI 1.6-5.1; p = 0.001), and GD (OR = 2.1; 95% CI 1.2 −3.7; p = 0.01). FP t18s were associated with fetal loss (OR= 8.9 (95% CI 2.9-27) p = 0.002. CONCLUSION: FP from first trimester screening for t21 and t18 are associated with adverse obstetric outcomes.

Preeclampsia severa, crecimiento intrauterino restringido precoz y miocardiopatía periparto: una fisiopatología antiangiogénica común / Severe pre-eclampsia, early-onset intrauterine growth restriction, and peripartum cardiomyopathy: a common antiangiogenic pathophysiology

La fuerte relación epidemiológica que existe entre la preeclampsia y la miocardiopatía periparto sugiere que las dos enfermedades comparten una fisiopatología antiangiogénica y considera que ambas contribuyen a la morbilidad y mortalidad cardiovascular significativa en las pacientes embarazadas. El s-FLT1, una enzima recientemente identificada en la familia de la tirosina quinasa, parece ser un agente antiangiogénico con poder cardiotóxico, que aparece elevado tanto en la miocardiopatía periparto como en la preeclampsia. A la luz de la fuerte asociación entre los dos procesos, parece recomendable que las mujeres con preeclampsia no sean excluidas de los estudios futuros de la miocardiopatía periparto

The strong epidemiological link between pre-eclampsia and peripartum cardiomyopathy suggests that the two diseases share an anti-angiogenic pathophysiology. Both contribute to significant cardiovascular morbidity and mortality in pregnant patients. The s-FLT1, a recently identified family of tyrosine kinase enzyme, appears to be an anti-angiogenic agent with cardiotoxic power, which appears high in both peripartum cardiomyopathy and pre-eclampsia. Considering the strong association between the two processes, it is recommended that women with pre-eclampsia are not excluded from future studies of peripartum cardiomyopathy

La embolización arterial selectiva como alternativa terapéutica en el manejo del hematoma puerperal disecante / Selective arterial embolization as a therapeutic alternative in the management of puerperal dissecting haematoma

La mayoría de los hematomas puerperales son secundarios a laceraciones o desgarros producidos como consecuencia del traumatismo del parto, y rara vez tienen consecuencias maternas importantes. En ocasiones, estos hematomas pueden expandirse y disecar el tejido circundante suponiendo una complicación obstétrica potencialmente grave. Aunque es necesario un diagnóstico y tratamiento precoz, su manejo no está estandarizado y es causa de controversia ya que la literatura no es concluyente en cuanto a los beneficios del tratamiento conservador respecto al quirúrgico. El propósito de presentar este caso es demostrar la importancia de las técnicas de imagen para la identificación del lugar de la hemorragia y la posibilidad de realizar una embolización arterial selectiva como alternativa eficaz para el control de la misma (AU)

Most puerperal haematomas are produced by lacerations or tears as a result of birth trauma and rarely have significant maternal consequences. These hematomas can sometimes expand and dissect surrounding tissues, becoming a potentially serious obstetric complication. Although early diagnosis and treatment is necessary, the management of these entities remains controversial and there is no conclusive evidence on the benefits of surgery compared with non-surgical treatment. The present case report illustrates the importance of imaging techniques in identifying the site of bleeding and the possibility of selective arterial embolization as an effective alternative for bleeding control (AU)

La miocardiopatía periparto como causa de insuficiencia cardiaca en el embarazo y el puerperio / Peripartum cardiomyopathy as a cause of heart failure in pregnancy and the postpartum period

La miocardiopatía periparto es una enfermedad con una elevada morbimortalidad y que, a pesar de sus riesgos potenciales, no es posible prevenirla. Por ello, solo podremos actuar sobre los factores de riesgo asociados a su aparición y sobre las complicaciones una vez diagnosticada. Debido a su baja incidencia, es difícil el conocimiento real de esta enfermedad, ya que se basa en artículos publicados sobre series reducidas de casos. El propósito de esta revisión es realizar una descripción de la fisiopatología, las manifestaciones clínicas, el diagnóstico y el tratamiento de la enfermedad, enfocada principalmente en el manejo obstétrico de la gestante (AU)

Peripartum cardiomyopathy is a serious disease with high morbidity and mortality. Despite its potential risks, prevention is not possible. Therefore, the only feasible strategy is to treat the risk factors and associated complications. Due to the low incidence of peripartum cardiomyopathy, is difficult to achieve real knowledge of this disease, which is based on small case series. This review aims to describe the pathophysiology, clinical manifestations, diagnosis and treatment of peripartum cardiomyopathy, with special emphasis on the obstetric management of pregnant women (AU)